Spotlight Group (”Spotlight” eller ”Bolaget”) redovisade en nettoomsättning långt under förväntan, f...
Kvartalet bjöd på en rekordhög tillväxt och fortsatt tydlig trend mot lönsamhet.
Elanders mötte svag efterfrågan under Q3 och ett högre ränteläge pressar vinsten.
Redeye considers Arise’s Q3 report to be very solid and almost completely in line with our estimates...
Redeye comments on Maximum Entertainment’s Q3-results which came in strong and clearly beat our fore...
Redeye updates on EG7 following its Q3-results which saw lower topline than expected while EBITDA wa...
Redeye has revised our estimates and fair value range following Physitrack’s Q3 2023 report, which c...
Redeye expects an eventful 2024 for Lifecare following the Q3 report, which sported slightly higher ...
Redeye provides a retake of the investment case in Respiratorius following its Q3 2023 report and a ...
Redeye provides a preview ahead of Fragbite Groups Q3 2023 report while also discussing its latest a...
Redeye shares its insights after Carasent’s Capital Markets Day (CMD) and revises its estimates acco...
Algo could potentially start to rebound in the coming quarters '23e-'25e sales down 9-15% '24e EV/EB...
I det tredje kvartalet uppgick nettoomsättningen till 193,3 MSEK (95,4), en ökning med cirka 102,8 %...
Equity analyst Markus Almerud discusses Zwipe after the announcement of the rights issue.
The number of patients continued to grow strongly during Q3-23 for STENOCARE A/S (“STENOCARE” or “th...
Rapportkommentar Q3 Corlines Q3-rapport levde inte upp till marknadens förväntningar.
Redeye notes that Impact Coatings is making further progress in China and within business area auton...
Q3 EBITDA of -0.3m vs ABGSCe 0.9m Strong financial position - Holds SEK 6.
Redeye concludes that the figures in Physitrack’s Q3 2023 report were generally in line with our est...
Exel’s CMD added details to its new strategy. Many important decisions are still to be worked out, b...
